(19)
(11) EP 3 311 666 B8

(12) CORRECTED EUROPEAN PATENT SPECIFICATION
Note: Bibliography reflects the latest situation

(15) Correction information:
Corrected version no 1 (W1 B1)

(48) Corrigendum issued on:
23.06.2021 Bulletin 2021/25

(45) Mention of the grant of the patent:
05.05.2021 Bulletin 2021/18

(21) Application number: 17193280.9

(22) Date of filing: 17.08.2011
(51) International Patent Classification (IPC): 
A01N 35/00(2006.01)
C07D 319/18(2006.01)
C07D 405/10(2006.01)
C07D 409/06(2006.01)
C07C 49/784(2006.01)
A61P 25/00(2006.01)
 A61K 31/12(2006.01)
C07D 405/06(2006.01)
C07D 407/10(2006.01)
C07D 409/10(2006.01)
C07D 213/50(2006.01)

(54)

DIKETONES AND HYDROXYKETONES AS CATENIN SIGNALING PATHWAY ACTIVATORS

DIKETONE UND HYDROXYKETONE ALS CATENINSIGNALWEG-AKTIVATOREN

DICÉTONES ET HYDROXYDICÉTONES UTILES EN TANT QU'ACTIVATEURS DE LA VOIE DE SIGNALISATION DE LA CATÉNINE

(84) Designated Contracting States:
AL AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HR HU IE IS IT LI LT LU LV MC MK MT NL NO PL PT RO RS SE SI SK SM TR

(30) Priority: 18.08.2010 US 374687 P
29.12.2010 US 201061427974 P

(43) Date of publication of application:
25.04.2018 Bulletin 2018/17

(60) Divisional application:
21167222.5

(62) Application number of the earlier application in accordance with Art. 76 EPC:
11818727.7 / 2605652

(73) Proprietor: BioSplice Therapeutics, Inc.
San Diego, CA 92121 (US)

(72) Inventors:
  • KC, Sunil Kumar
    San Diego, CA 92127 (US)
  • WALLACE, David Mark
    San Diego, CA 92121 (US)
  • HOOD, John
    San Diego, CA 92130 (US)
  • BARROGA, Charlene F.
    San Diego, CA 92122 (US)

(74) Representative: D Young & Co LLP 
120 Holborn
London EC1N 2DY
London EC1N 2DY (GB)


(56) References cited: : 
WO-A1-2010/075551
   
       
    Note: Within nine months from the publication of the mention of the grant of the European patent, any person may give notice to the European Patent Office of opposition to the European patent granted. Notice of opposition shall be filed in a written reasoned statement. It shall not be deemed to have been filed until the opposition fee has been paid. (Art. 99(1) European Patent Convention).